Infectious Agents and Cancer (Aug 2009)

No evidence for WU polyomavirus infection in chronic obstructive pulmonary disease

  • Ringshausen Felix C,
  • Heckmann Marei,
  • Weissbrich Benedikt,
  • Neske Florian,
  • Borg Irmgard,
  • Knoop Umut,
  • Kronsbein Juliane,
  • Hauptmeier Barbara M,
  • Schultze-Werninghaus Gerhard,
  • Rohde Gernot

DOI
https://doi.org/10.1186/1750-9378-4-12
Journal volume & issue
Vol. 4, no. 1
p. 12

Abstract

Read online

Abstract Human polyomaviruses are known to cause persistent or latent infections, which are reactivated under immunosuppression. Polyomaviruses have been found to immortalize cell lines and to possess oncogenic properties. Moreover, the recently discovered Merkel cell polyomavirus shows a strong association with human Merkel cell carcinomas. Another novel human polyomavirus, WU polyomavirus (WUPyV), has been identified in respiratory specimens from patients with acute respiratory tract infections (ARTI). WUPyV has been proposed to be a pathogen in ARTI in early life and immunocompromised individuals, but so far its role as a causative agent of respiratory disease remains controversial. The objective of our study was to determine the prevalence of WUPyV infections in adult hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) and to establish its potential clinical relevance by comparison to patients with stable COPD hospitalized for other reasons than acute exacerbation of COPD (AE-COPD). A total of 378 respiratory specimens, each 189 induced sputum and nasal lavage samples from 189 patients, who had been recruited in a prospective 2:1 ratio case-control set-up between 1999 and 2003, were evaluated for the presence of WUPyV DNA by real-time PCR. In the present study we could not detect WUPyV DNA in 378 respiratory specimens from 189 adult hospitalized patients with AE-COPD and stable COPD in four consecutive years. Persistence of viral replication or reactivation of latent WUPyV infection did not occur. WUPyV may not play a major role in adult immunocompetent patients with AE-COPD and stable COPD.